Written by the Nuvirox Research Team
Key Points
- Kava has real randomized-trial support for anxiety-linked sleep disturbance, but the largest single trial ever run on it found no benefit over placebo.
- The FDA and multiple international regulators have flagged kava for rare but serious liver injury; short courses of properly prepared root extract appear far safer than the acetonic extracts implicated in older case reports.
- If you take any other medication metabolized by the liver, or have any history of liver disease, talk to a doctor before trying kava — this is not a supplement to self-experiment with casually.
Short answer: kava has some of the better randomized-trial support of any herbal sleep aid for anxiety-linked insomnia, but it also carries a real, if rare, liver safety signal that most other sleep botanicals simply don't. That combination — genuine efficacy signal, genuine safety signal — makes kava one of the more interesting and more complicated entries in the herbal sleep aisle.
What is kava, and why do people take it for sleep?
Kava (Piper methysticum) is a plant from the Pacific Islands, traditionally prepared as a ceremonial drink from its root. The active compounds, kavalactones, are thought to interact with GABA receptors in the brain — the same inhibitory system targeted by benzodiazepines and alcohol, and shared, in different ways, by botanicals like hops and skullcap, though kava's action is far gentler. People reach for kava less because they want to fall asleep directly and more because they're anxious, tense, or wound up at bedtime, and kava is marketed first as an anti-anxiety botanical whose sleep benefit rides along with a calmer nervous system.
Does kava actually help you sleep?
The honest answer is: it depends heavily on which trial you're looking at, and that split is worth sitting with rather than averaging away.
On the positive side, a multicenter, randomized, double-blind trial gave 61 patients with anxiety-related sleep disturbance either 200 mg of a standardized kava extract (WS 1490) or placebo for four weeks. The kava group showed statistically significant improvement in both the "quality of sleep" and "recuperative effect after sleep" subscales of a validated sleep questionnaire, alongside improvement on anxiety measures. A separate 2013 randomized trial using an aqueous kava extract in generalized anxiety disorder found a 26% remission rate versus 6% on placebo over eight weeks, with genetic variation in GABA transporter genes partly predicting who responded.
On the negative side sits the largest trial kava has ever been through: an internet-based, randomized, placebo-controlled study of 1,551 participants recruited from 45 states, designed specifically to test whether kava helps anxiety and whether valerian helps sleep. Neither herb beat placebo. And a 2020 16-week randomized trial of 171 people with generalized anxiety disorder found no difference in anxiety reduction between kava and placebo, with placebo actually showing a higher remission rate by the end.
A systematic review pooling five clinical trials (330 people total) calculated a risk ratio of 1.50 in favor of kava for anxiety response — a real but modest effect, and the review's authors were explicit that kava looks like a reasonable short-term option, not a replacement for longer-term anti-anxiety care.
Why does kava carry a liver warning?
This is the part that separates kava from most of the other botanicals in this aisle. Regulators in several countries, including a formal FDA advisory, have flagged kava-containing supplements for a rare but real risk of severe liver injury, including cases requiring transplant. A clinical review of kava hepatotoxicity examined 14 well-documented cases of liver injury worldwide and found the causality assessment "probable" or "highly probable" for kava in five of them, with risk concentrated among people who overdosed, used it for a prolonged period, or combined it with other liver-taxing drugs or supplements. Notably, the injury pattern showed up across aqueous, ethanolic, and acetonic extracts alike, which suggests raw material quality — not just extraction method — plays a role.
At the same time, a 2018 systematic review of seven randomized trials found no difference in liver-related adverse events between kava and placebo groups, and one 2013 trial using aqueous kava extract up to 240 mg of kavalactones daily found no changes in liver enzymes. Traditional Pacific Island preparations, using water-based extraction of the root, appear to carry meaningfully lower risk than the concentrated ethanolic and acetonic extracts more common in Western supplements — and a subset of researchers estimate the population-level risk from any kava exposure is under 0.3 cases per million doses, lower than several prescription anti-anxiety drugs.
None of that erases the signal. It reframes it: kava's liver risk looks concentrated in high doses, prolonged use, poor-quality raw material, and combination with other hepatotoxic substances (including alcohol) — which is exactly why short courses of a well-sourced, aqueous-extract kava product carry a different risk profile than daily, indefinite use of a cheap acetonic extract.
Who should not take kava
See a doctor before trying kava if you have any history of liver disease, drink alcohol regularly, take any medication processed by the liver (including many antidepressants and anti-anxiety medications), are pregnant or breastfeeding, or plan to use it for more than a few weeks at a time. If you notice yellowing of the skin or eyes, unusual fatigue, dark urine, or abdominal pain while taking kava, stop immediately and seek medical attention. If you'd rather avoid liver-safety questions altogether, our melatonin and valerian root comparison covers a lower-risk starting point.
How is kava typically dosed in trials?
The positive sleep trial used 200 mg daily of a standardized extract (WS 1490) for four weeks. The positive anxiety trials used aqueous extracts up to 240 mg of kavalactones daily. Traditional ceremonial kava, prepared as a water-based drink, delivers variable kavalactone content depending on preparation strength and is harder to standardize than encapsulated extract. Most human trials ran four to sixteen weeks — there is very little data on daily use beyond that window, which is itself part of the honest limitation here.
What kava won't do
Kava is not a knockout sedative and isn't designed to force sleep onset the way a sleep medication or high-dose antihistamine might. Its trial evidence is strongest for anxiety-linked sleep disturbance specifically — people whose racing thoughts or tension are the barrier to sleep — and weaker or absent for general insomnia unrelated to anxiety. If your sleep problem is a diagnosed sleep disorder, chronic pain, or a medical condition, kava is not a substitute for that evaluation.
Study Snapshot: Lehrl 2004 kava sleep trial
| Design | Multicenter, randomized, double-blind, placebo-controlled |
| Participants | 61 adults with anxiety-related sleep disturbance |
| Dose | 200 mg/day standardized extract WS 1490 |
| Duration | 4 weeks |
| Result | Significant improvement in sleep quality and recuperative effect vs. placebo |
Frequently asked questions
Is kava legal in the US?
Yes, kava is sold legally as a dietary supplement in the United States, though the FDA has issued a consumer advisory about liver injury risk. It has been restricted or banned in some other countries at various points.
Can I take kava with alcohol?
No. Combining kava with alcohol or other substances metabolized by the liver increases the risk of liver injury and is specifically flagged as a risk factor in clinical reviews.
How long can I safely take kava?
Most positive trials ran 4 to 16 weeks. There isn't good safety data on continuous daily use beyond that, so many clinicians recommend treating it as a short-course option rather than an everyday supplement.
Does kava interact with sleep medications?
Because kava affects GABA signaling, combining it with benzodiazepines, other sedatives, or alcohol can compound sedation. Talk to a doctor before combining kava with any prescription sleep or anxiety medication.
Because kava carries a documented, if rare, liver-injury signal, we'd encourage anyone considering it — especially alongside other supplements or medications — to loop in a doctor or pharmacist first. Sleep+ Restore does not contain kava; it's built around melatonin, St. John's Wort, and 5-HTP instead.
From Nuvirox
Why we formulated Sleep+ Restore
Sleep+ Restore combines melatonin with St. John’s Wort and 5-HTP in a single nightly formula, designed for people whose sleep trouble is tangled up with a low, unsettled mood rather than a purely mechanical sleep-hygiene problem.
Learn more about Sleep+ Restore →Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
The bottom line
Kava has genuine randomized-trial support for anxiety-linked sleep trouble, alongside a genuine, well-documented liver safety signal that most people considering it should take seriously rather than dismiss as internet scaremongering. If you decide to try it, short courses, a reputable aqueous-extract product, and a conversation with your doctor first are the reasonable way to do that.
References
- Sarris J, Stough C, Bousman CA, et al. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized placebo-controlled study. J Clin Psychopharmacol. 2013;33(5):643-648.
- Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SR. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. J Altern Complement Med. 2005. PMID: 16010204.
- Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders: results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disord. 2004;78(2):101-110. PMID: 14706720.
- Smith K, Leiras C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: a systematic review and analysis of randomized clinical trials. Complement Ther Clin Pract. 2018;33:107-117.
- Teschke R. Kava hepatotoxicity: a clinical review. Ann Hepatol. PMID: 20720265.
- Sarris J, et al. 16-week randomized trial of kava for generalized anxiety disorder (n=171), as summarized in Merck Manual Professional Edition, Special Subjects: Kava.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.